VAT Number: 998 076 935

Founded: December 2, 2011

KTIAS is a family owned small investment company.

The chairman of the board, Jan Olof G Karlsson has a PhD in pharmacology from Linköping University, where he also holds a postion as a docent (assistant professor) since 1991. The title of docent is typically a formal requirement for being a main supervisor for PhD students, and for serving as a member of an examination committee for evaluation of a doctoral thesis. Between 1991 and 2007 Karlsson supervised three PhD students and a number of Master degree students. Between 1992 and 2007 he worked as a senior scientist at Nycomed Imaging (that later become GE Healthcare ) in Oslo.     

He is one of the founders of PledPharma AB (Egetis), where he also worked a Chief Scientist Officer between 2007 and 2014. Karlsson is the main inventor of the company's patents. He has authored more than 80 scientific papers and is inventor on more than 10 patent families.   

PledPharmas original strategy was to develop PLED substances into effective rescue medicine, to be used for example in acute myocardial infarction, life-threatening paracetamol intoxication and life-threatening decrease in white blood cells in connection with chemotherapy in cancer patients.

KTIAS has invested in a medical project dealing with treatment of chronic neuropathy caused by platinum chemotherapy drugs. The method used to treat neuropathy is covered by patents granted in USA, Europe, China and Japan.The company is seeking a partner to develop this project into an approved drug.